T-cell co-stimulation modulator
This page covers all T-cell co-stimulation modulator drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CD80/CD86.
Targets
Phase 3 pipeline (1)
- Abatacept subcutaneous · Bristol-Myers Squibb · Immunology
Abatacept is a fusion protein that blocks T-cell co-stimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.
Patent intelligence
- t cell co stimulation modulator patent landscape — aggregated cliff calendar, attackable patents, originator estates